EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Trichomonas vaginalis Drug Targets and Their Role in Drug Discovery and Development

Mirna Samara Dié Alves, Ângela Sena-Lopes, Luiza Domingues Moron, Bárbara da Rocha Fonseca, Sibele Borsuk

Pharmaceutical Research · 2026

DOI: 10.1007/s11095-026-04098-0 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutical Research, 2026. Verfasst von Mirna Samara Dié Alves und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Biotecnologia Infecto-Parasitária, Centro de Desenvolvimento Tecnológico, Biotecnologia, Federal University of Pelotas - UFPel, Campus…. Hauptthemen laut MEDLINE: Trichomonas vaginalis, Drug Discovery, Trichomonas Infections, Antitrichomonal Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 201 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade Federal De Pelotas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trichomonas vaginalis is the causative agent of trichomoniasis, the most common and prevalent sexually transmitted infection (STI) globally, with about 156 million cases annually. Trichomoniasis is a critical public health problem, and it is aggravated due to its association with a higher risk of HIV-1 acquisition and transmission and complications such as preterm delivery and pelvic inflammatory disease. This STI is treated mainly through the 5-nitroimidazole class, specifically metronidazole and tinidazole. However, drug resistance, which can represent between 5 and 20% of clinical cases, and hypersensitivity reactions are a general concern. In this context, drug development for trichomoniasis is an ever-growing research field. Therefore, considering how important drug targets and the mechanism of action of compounds can be to drug discovery, there is a growing interest in better understanding how some molecules can be used as targets. This article offers an overview of T. vaginalis drug targets, their significance in metabolism, pathogenesis, or survival, and their contribution to drug development for trichomoniasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Trichomonas vaginalisDrug DiscoveryTrichomonas InfectionsAntitrichomonal AgentsAntiprotozoal AgentsTrichomonas VaginitisHumansAnimalsDrug Development

Stichwörter der Autor:innen

target deconvolutiontarget-based developmenttherapeutic targets

Substanzen

Antitrichomonal AgentsAntiprotozoal Agents

Autor:innen und Institutionen

  • Laboratório de Biotecnologia Infecto-Parasitária, Centro de Desenvolvimento Tecnológico, Biotecnologia, Federal University of Pelotas - UFPel, Campus Universitário s/n, Prédio 19, Pelotas, RS, 96010-900, Brazil.
  • Laboratório de Biotecnologia Infecto-Parasitária, Centro de Desenvolvimento Tecnológico, Biotecnologia, Federal University of Pelotas - UFPel, Campus Universitário s/n, Prédio 19, Pelotas, RS, 96010-900, Brazil. sibeleb…

Förderung

  • Universidade Federal De Pelotas

Zitieren

APA

Alves, M. S. D., Sena-Lopes, Â., Moron, L. D., Fonseca, B. D. R., & Borsuk, S. (2026). Trichomonas vaginalis Drug Targets and Their Role in Drug Discovery and Development. Pharmaceutical Research. https://doi.org/10.1007/s11095-026-04098-0

Vancouver

Alves MSD, Sena-Lopes Â, Moron LD, Fonseca BDR, Borsuk S. Trichomonas vaginalis Drug Targets and Their Role in Drug Discovery and Development. Pharmaceutical Research. 2026. doi:10.1007/s11095-026-04098-0

BibTeX
@article{Alves2026,
  author = {Alves, Mirna Samara Dié and Sena-Lopes, Ângela and Moron, Luiza Domingues and Fonseca, Bárbara da Rocha and Borsuk, Sibele},
  title = {Trichomonas vaginalis Drug Targets and Their Role in Drug Discovery and Development},
  journal = {Pharmaceutical Research},
  year = {2026},
  doi = {10.1007/s11095-026-04098-0}
}
Kostenlos starten →